Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.61 |
| ▸ | NAAA | Q02083 | 14/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.50 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8893237 | 0.98 | EPHX1 (0.59) | EPHX1NAAASMN1; SMN2ASAH1FKBP1A | |
| SCHEMBL6931991 | 0.94 | SMN1; SMN2 (0.56) | EPHX1NAAASMN1; SMN2FKBP1A | |
| SCHEMBL19842292 | 0.94 | SMN1; SMN2 (0.56) | EPHX1NAAASMN1; SMN2FKBP1A | |
| SCHEMBL13034075 | 0.92 | SMN1; SMN2 (0.54) | EPHX1NAAASMN1; SMN2FKBP1A | |
| SCHEMBL12406393 | 0.91 | EPHX1 (0.53) | EPHX1NAAASMN1; SMN2ASAH1FKBP1A | |
| SCHEMBL23471057 | 0.90 | ALDH1A1 (0.50) | EPHX1NAAASMN1; SMN2ASAH1FKBP1A | |
| SCHEMBL11696307 | 0.89 | ALDH1A1 (0.48) | EPHX1NAAASMN1; SMN2FKBP1A | |
| SCHEMBL23471248 | 0.89 | ALDH1A1 (0.48) | EPHX1NAAASMN1; SMN2FKBP1A | |
| SCHEMBL11693755 | 0.89 | ALDH1A1 (0.48) | EPHX1NAAASMN1; SMN2FKBP1A | |
| SCHEMBL8896243 | 0.86 | EPHX1 (0.45) | EPHX1NAAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103962091-A | Method for separating EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) by using silver ion modified amino silica gel | UNIV DALIAN POLYTECHNIC | 2014-08-06 | — | — | CN | claimed |
| CN-101363819-B | Quality control method for yuye qinghuo capsule | GUANGXI BOKE PHARMACEUTICAL CO LTD | 2012-04-18 | — | — | CN | claimed |
| CN-101363819-A | Quality control method for yuye qinghuo capsule | GUANGXI BOKE PHARMACEUTICAL CO (CN) | 2009-02-11 | — | — | CN | claimed |
| CN-117665188-A | Quality detection method of anti-tuberculosis medicinal granules | 桂林三金药业股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-103962091-A | Method for separating EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) by using silver ion modified amino silica gel | UNIV DALIAN POLYTECHNIC | 2014-08-06 | — | — | CN | disclosed |
| CN-102288595-B | Method for continuously measuring tungsten and molybdenum by taking citric acid and hydrogen peroxide as complexing agents | NORTHWEAT RES INST OF MINING & METALLURG INST | 2012-11-21 | — | — | CN | disclosed |
| CN-101363819-B | Quality control method for yuye qinghuo capsule | GUANGXI BOKE PHARMACEUTICAL CO LTD | 2012-04-18 | — | — | CN | disclosed |
| EP-2423199-A1 | Substituted imidazoles and their use as pesticides | Pfizer Limited (GB) | 2012-02-29 | — | — | EP | disclosed |
| CN-102288595-A | Method for continuously measuring tungsten and molybdenum by taking citric acid and hydrogen peroxide as complexing agents | — | 2011-12-21 | — | — | CN | disclosed |
| US-7972763-B2 | Patterns having high resolution; used for semiconductor microfabrication employing a lithography | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-07-05 | — | — | US | disclosed |
| US-7825149-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2010-11-02 | — | — | US | disclosed |
| US-20090312326-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-7592362-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| US-7547718-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-06-16 | — | — | US | disclosed |
| US-7544706-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-06-09 | — | — | US | disclosed |
| CN-101363819-A | Quality control method for yuye qinghuo capsule | GUANGXI BOKE PHARMACEUTICAL CO (CN) | 2009-02-11 | — | — | CN | disclosed |
| US-20080153036-A1 | Chemically amplified positive resist compostion | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-06-26 | — | — | US | disclosed |
| US-20080125473-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2008-05-29 | — | — | US | disclosed |
| US-20080119536-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2008-05-22 | — | — | US | disclosed |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | PFIZER INC. (US) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125473-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | EPHX1 1428/4885NAAA 1565/4885SMN1; SMN2 1394/4885 |
| US-20090312326-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | EPHX1 1428/4885NAAA 1565/4885SMN1; SMN2 1394/4885 |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | EPHX1 1428/4885NAAA 1565/4885SMN1; SMN2 1394/4885 |
| US-20080119536-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | EPHX1 1428/4885NAAA 1565/4885SMN1; SMN2 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.